Rifabutin-Loaded Nanostructured Lipid Carriers as a Tool in Oral Anti-Mycobacterial Treatment of Crohn’s Disease

• Published in: Nanomaterials (Basel, Switzerland) Switzerland), 2020-10, Vol.10 (11), p.2138
• Main Authors: Rouco, Helena, Diaz-Rodriguez, Patricia, Gaspar, Diana P., Gonçalves, Lídia M. D., Cuerva, Miguel, Remuñán-López, Carmen, Almeida, António J., Landin, Mariana
• Format: Article
• Language: English
• Subjects: Caco-2 cells; cell uptake; Crohn’s disease; nanostructured lipid carriers; oral administration; rifabutin
• ISSN: 2079-4991; 2079-4991
• DOI: 10.3390/nano10112138

Oral anti-mycobacterial treatment of Crohn’s disease (CD) is limited by the low aqueous solubility of drugs, along with the altered gut conditions of patients, making uncommon their clinical use. Hence, the aim of the present work is focused on the in vitro evaluation of rifabutin (RFB)-loaded Nanostructured lipid carriers (NLC), in order to solve limitations associated to this therapeutic approach. RFB-loaded NLC were prepared by hot homogenization and characterized in terms of size, polydispersity, surface charge, morphology, thermal stability, and drug payload and release. Permeability across Caco-2 cell monolayers and cytotoxicity and uptake in human macrophages was also determined. NLC obtained were nano-sized, monodisperse, negatively charged, and spheroidal-shaped, showing a suitable drug payload and thermal stability. Furthermore, the permeability profile, macrophage uptake and selective intracellular release of RFB-loaded NLC, guarantee an effective drug dose administration to cells. Outcomes suggest that rifabutin-loaded NLC constitute a promising strategy to improve oral anti-mycobacterial therapy in Crohn’s disease.